These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36125916)

  • 1. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit.
    Kakkar V; Assassi S; Allanore Y; Kuwana M; Denton CP; Khanna D; Del Galdo F
    Curr Opin Rheumatol; 2022 Nov; 34(6):357-364. PubMed ID: 36125916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.
    Paradowska-Gorycka A; Wajda A; Stypinska B; Walczuk E; Rzeszotarska E; Walczyk M; Haladyj E; Romanowska-Prochnicka K; Felis-Giemza A; Lewandowska A; Olesińska M
    Clin Exp Immunol; 2021 Apr; 204(1):49-63. PubMed ID: 33336388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic sclerosis and lupus: points in an interferon-mediated continuum.
    Assassi S; Mayes MD; Arnett FC; Gourh P; Agarwal SK; McNearney TA; Chaussabel D; Oommen N; Fischbach M; Shah KR; Charles J; Pascual V; Reveille JD; Tan FK
    Arthritis Rheum; 2010 Feb; 62(2):589-98. PubMed ID: 20112391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis.
    Andraos R; Ahmad A; Eriksson P; Dahlström Ö; Wirestam L; Dahle C; Hesselstrand R; Bengtsson AA; Jönsen A; Andréasson K; Sjöwall C
    Lupus Sci Med; 2022 Dec; 9(1):. PubMed ID: 36581379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
    Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
    Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody.
    Wang B; Higgs BW; Chang L; Vainshtein I; Liu Z; Streicher K; Liang M; White WI; Yoo S; Richman L; Jallal B; Roskos L; Yao Y
    Clin Pharmacol Ther; 2013 Jun; 93(6):483-92. PubMed ID: 23511714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
    Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.
    Mariotti B; Servaas NH; Rossato M; Tamassia N; Cassatella MA; Cossu M; Beretta L; van der Kroef M; Radstake TRDJ; Bazzoni F
    Front Immunol; 2019; 10():100. PubMed ID: 30804934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus.
    Luo S; Wang Y; Zhao M; Lu Q
    Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.
    Hagberg N; Rönnblom L
    Scand J Immunol; 2015 Sep; 82(3):199-207. PubMed ID: 26099519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis.
    Carmona FD; Martin JE; Beretta L; Simeón CP; Carreira PE; Callejas JL; Fernández-Castro M; Sáez-Comet L; Beltrán E; Camps MT; Egurbide MV; ; Airó P; Scorza R; Lunardi C; Hunzelmann N; Riemekasten G; Witte T; Kreuter A; Distler JH; Madhok R; Shiels P; van Laar JM; Fonseca C; Denton C; Herrick A; Worthington J; Schuerwegh AJ; Vonk MC; Voskuyl AE; Radstake TR; Martín J
    PLoS One; 2013; 8(1):e54419. PubMed ID: 23372721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha: a therapeutic target in systemic lupus erythematosus.
    Crow MK
    Rheum Dis Clin North Am; 2010 Feb; 36(1):173-86, x. PubMed ID: 20202598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis.
    Tozkır JD; Tozkır H; Gürkan H; Dönmez S; Eker D; Pamuk GE; Pamuk ÖN
    Clin Rheumatol; 2016 Apr; 35(4):919-25. PubMed ID: 26960450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.
    Chiche L; Jourde-Chiche N; Whalen E; Presnell S; Gersuk V; Dang K; Anguiano E; Quinn C; Burtey S; Berland Y; Kaplanski G; Harle JR; Pascual V; Chaussabel D
    Arthritis Rheumatol; 2014 Jun; 66(6):1583-95. PubMed ID: 24644022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I interferon dysregulation in Systemic Sclerosis.
    Skaug B; Assassi S
    Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.
    Chasset F; Ribi C; Trendelenburg M; Huynh-Do U; Roux-Lombard P; Courvoisier DS; Chizzolini C;
    Rheumatology (Oxford); 2020 Nov; 59(11):3468-3478. PubMed ID: 32375176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
    Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.